Literature DB >> 8378618

Experimental concurrent infections with Ostertagia ostertagi and Cooperia oncophora in the calf.

F Satrija1, P Nansen.   

Abstract

An experiment was conducted to investigate the effects of experimental concurrent infection with Ostertagia ostertagia and Cooperia oncophora compared with the effects of monospecific infections with O ostertagi under conditions designed to mimic natural conditions on pasture during a grazing season. The present experiment was not able to demonstrate any significant effect of C oncophora on the course of an O ostertagi infection. Neither did C oncophora influence the build up of immunity to O ostertagi as demonstrated by post mortem worm count results from challenge infections with hypobiosis-prone larvae.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8378618     DOI: 10.1016/0034-5288(93)90040-m

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  4 in total

1.  The effects of early-season treatments with doramectin on set-stocked calves naturally exposed to trichostrongyles.

Authors:  F Satrija; P Nansen
Journal:  Vet Res Commun       Date:  1996       Impact factor: 2.459

2.  Modelling the consequences of targeted selective treatment strategies on performance and emergence of anthelmintic resistance amongst grazing calves.

Authors:  Zoe Berk; Yan C S M Laurenson; Andrew B Forbes; Ilias Kyriazakis
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-11-16       Impact factor: 4.077

3.  A simulation model to investigate interactions between first season grazing calves and Ostertagia ostertagi.

Authors:  Zoe Berk; Stephen C Bishop; Andrew B Forbes; Ilias Kyriazakis
Journal:  Vet Parasitol       Date:  2016-05-07       Impact factor: 2.738

4.  A stochastic model to investigate the effects of control strategies on calves exposed to Ostertagia ostertagi.

Authors:  Zoe Berk; Yan C S M Laurenson; Andrew B Forbes; Ilias Kyriazakis
Journal:  Parasitology       Date:  2016-08-30       Impact factor: 3.234

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.